Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17019
Country/Region: South Africa
Year: 2016
Main Partner: Anova Health Institute
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $1,990,755 Additional Pipeline Funding: $731,777

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $472,729
Care: TB/HIV (HVTB) $646,426
Care: Pediatric Care and Support (PDCS) $41,778
Testing: HIV Testing and Counseling (HVCT) $150,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $83,555
Treatment: Adult Treatment (HTXS) $554,489
Treatment: Pediatric Treatment (PDTX) $41,778
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: 15-19 Male 2017 1,599
HTS_TST Age/sex: 20-24 Male 2017 3,735
HTS_TST Age/sex: 25-49 Male 2017 3,733
HTS_TST Age/sex: 50+ Male 2017 1,599
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 21,821
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 21,821
HTS_TST Service Delivery Point (Community): Other 2017 11,155
HTS_TST Service Delivery Point (Facility): Index testing 2017 1,003
HTS_TST Service Delivery Point (Facility): VCT 2017 9,663
HTS_TST Sum of Age/Sex disaggregates 2017 10,666
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 21,821
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 21,821
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 286
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 672
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 672
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 286
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,585
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2017 14,871
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2017 14,871
KP_PREV Total estimated number of key population in the catchment area 2017 74,910
KP_PREV_den By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) 2017 74,910
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 785
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 785
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 785
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 57
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 512
TB_SCREENDX Screen Result: Screened Positive for TB 2017 569
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 18,962
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 18,962
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,195
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 1,195
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 1,366
TX_CURR Age/Sex: 15-19 Male 2017 2,380
TX_CURR Age/Sex: 20-24 Male 2017 5,553
TX_CURR Age/Sex: 25-49 Male 2017 5,552
TX_CURR Age/Sex: 50+ Male 2017 2,379
TX_CURR Aggregated Age/Sex: 15+ Male 2017 15,864
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 15,864
TX_CURR Sum of age/sex disaggregates 2017 2,380
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 15,864
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 15,864
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 3,749
TX_NEW By Age/Sex: 15-19 Male 2017 561
TX_NEW By Age/Sex: 20-24 Male 2017 1,314
TX_NEW By Age/Sex: 25-49 Male 2017 1,312
TX_NEW By Age/Sex: 50+ Male 2017 562
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 3,749
TX_NEW Sum of Age/Sex disaggregates 2017 3,749
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 3,749
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 14,277
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 12,848
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 12,848
TX_PVLS Numerator: Indication: Routine 2017 12,848
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 14,277
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,316
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,074
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,072
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,317
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 8,779
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 8,779
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 9,339
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,399
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,271
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,269
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,399
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 9,339
Cross Cutting Budget Categories and Known Amounts Total: $1,990,000
Condoms: Commodities $400,000
Key Populations: MSM and TG $1,590,000
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Collection and use of strategic information
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Monitoring and evaluation of MSM/TG programs
Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG